Download
1 / 6
60 likes | 73 Views
Hemoglobinopathy is a genetic disorder that causes structural abnormalities in<br>hemoglobin molecules, particularly defective globin chains. Hemoglobinopathies are<br>inherited single-gene disorders of which sickle cell disease is the most common kind.<br>Read more at: https://www.alliedmarketresearch.com/hemoglobinopathies-market
E N D
World Hemoglobinopathies Market Opportunities and Forecasts, 2017-2023
Hemoglobinopathyis a genetic disorder that causes structural abnormalities in hemoglobin molecules, particularly defective globin chains. Hemoglobinopathies are inherited single-gene disorders of which sickle cell disease is the most common kind. There is a high prevalence of Hemoglobinopathies in Africa, Southeast Asia and the Mediterranean basin. If left untreated, critical cases of hemoglobinopathies lead to anemia, organ dysfunction or death. Gel electrophoresis and complete blood count are used as diagnostic tests to determine the presence of hemoglobinopathies.
The disease does not have a permanent cure; this has resulted in a growing demand for new product innovations in the pharmaceutical sector. Additionally, the high prevalence of the disease and the national control program are driving the need for drug therapy in developing economies. • Alnylam Pharmaceuticals, Gamilda Cell, Sangamo Biosciences, Cancer Therapeutics CRC Pty Ltd and Biogen Idec are some of the key players in this market. These companies have invested huge sums of money in research and development of hemoglobinopathies to develop a permanent cure for this disease. • NiCord, ZFP and ALN-TMP are some of the current products available in the market. Companies have adopted the strategy of collaboration and licensing to supplement their research activities.
KEY BENEFITS • The report provides an overview of the global hemoglobinopathies market, which includes drivers, restraints and opportunities to help professionals better understand market behavior • Detailed information regarding R&D activities, pipeline research, partnerships, licensing and collaborations in the global hemoglobinopathies market would be informative for professionals in the corporate sector • Pin-point analysis of geographic segments would help stakeholders identify opportunities for growth within the global hemoglobinopathies market • Porter’s Five Forces analysis examines the competitive structure of the global hemoglobinopathies market and would assist market strategists in their decision making process
MARKET BY PIPELINE THERAPEUTICS • NiCord • ZFP Transcription Factors • ALN-TMP • Drug Targeting PRMT5 • Drug Targeting Protein Arginine Methyltransferase 5 • MARKET BY GEOGRAPHY • North America • Europe • Asia-Pacific • LAMEA
Analyst Review : With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.
